HitGen, Inc. Hits Day Low at CNY 22.42 Amid Price Pressure

HitGen, Inc., a midcap player in the Pharmaceuticals & Biotechnology sector, experienced a notable decline today, with its stock price dropping by 6.78% on March 23, 2026. The stock reached an intraday low of CNY 22.42, reflecting a challenging day in the market. In terms of performance metrics, HitGen has faced a significant downturn over the past week, with a decrease of 12.36%. The one-month performance shows a more pronounced decline of 22.92%. However, on a yearly basis, the company has demonstrated resilience, boasting a 47.79% increase compared to the China Shanghai Composite's 13.33% gain. Financially, HitGen reported a remarkable growth in net profit of 114.98% as of September 25, alongside a pre-tax profit of CNY 43.75 million, which grew by 150.73%. The company also achieved its highest operating cash flow at CNY 204.8 million and a return on capital employed of 8.01%. Despite the recent volatility, HitGen's long-term performance has outpaced the broader market in various time frames, indicating a complex but noteworthy position in the industry.